Canakinumab in Patients With Active Hyper-IgD Syndrome

Phase 2 Completed 9 enrolled Novartis Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This pilot study is designed to evaluate the efficacy, the safety, and the pharmacokinetics (PK) / pharmacodynamics (PD) of canakinumab treatment in patients with HIDS.

Timeline

Start: 2011-03
Primary completion: 2014-07
Completion: 2014-07

Publications

Arostegui JI, Anton J, Calvo I, Robles A, Iglesias E, Lopez-Montesinos B, Banchereau R, Hong S, Joubert Y, Junge G, Pascual V, Yague J. Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome. Arthritis Rheumatol. 2017 Aug;69(8):1679-1688. doi: 10.1002/art.40146. Epub 2017 Jul 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Canakinumab	Monoclonal antibody	4 mg/kg	Subcutaneous
Subject	Canakinumab	Monoclonal antibody	300 mg	Subcutaneous

Canakinumab in Patients With Active Hyper-IgD Syndrome

Summary

Timeline

Publications

Drugs

Indications